iJOBS Career Panel: Merck
Thursday February 10:30-12pm
Piscataway

Contact Information

Gregory Adam: email: Gregory_adam@merck.com phone: 215-652-4415
Allison Kemper: email: golball@merck.com phone: 215-652-3264
William Rose: email: William.rose@merck.com phone: 215-652-2509
Laura Struzyna: email: laura.struzyna@merck.com phone: 215-652-6207

Gregory C. Adam, Ph.D.

After earning a B.S. in chemistry and a B.A. in biology at Southern Methodist University, Gregory Adam earned his Ph.D. from the Scripps Research Institute in La Jolla, CA, where his thesis in the labs of Benjamin Cravatt and Erik Sorensen focused on developing a non-directed approach to activity-based protein profiling. He moved to Merck Research Labs in 2003 and joined a newly formed Target Validation department as a member of a team tasked with the development and implementation of an Affinity Selection/Mass Spectrometry platform for small molecule lead identification. In 2009, Greg transferred to the department of Screening and Protein Sciences in North Wales, PA, where he focused on the development, miniaturization, and execution biochemical and cell-based assays utilizing a wide range of technologies for uHTS screening including high throughput mass spectrometry. In 2016, Greg transitioned to a Principal Scientist role in the Quantitative Biosciences department in West Point, PA where he leads a team focused on the development and execution of biochemical and biophysical assays to support neuroscience and infectious disease programs as well as Chemical Biology approaches for phenotypic screening.

Allison Kemper, Ph.D.

Allison earned her B.S. in Biochemistry from Stony Brook University and her Ph.D. in Pharmacology from Yale University. While at Yale, her Ph.D. work focused on developing biochemical assays for characterizing protease exosite contributions to substrate targeting. Her work also focused on developing scalable biochemical screening methods for identifying protease exosite inhibitors. Following completion of her Ph.D. in 2016, Allison joined the American Society for Biochemistry and Molecular Biology as a Diversity & Education Coordinator

in Washington, D.C. In this position, she coordinated the development, marketing, and hosting of national level education, professional development, and diversity & inclusion programs for undergraduate students through early career scientists. In 2018, she returned to the bench, taking a position at Merck as a Senior Scientist in the Quantitative Biosciences department. In her current position, she develops and executes biochemical assays to support neuroscience and infectious disease programs, with an emphasis on developing assays that provide increased throughput capabilities for project teams.

William A Rose II, Ph.D.

William is an Associate Principal Scientist at Merck & Co., West Point PA, where William performs in vivo studies to support pipeline programs in infectious diseases and other therapeutic areas. William has worked at Merck for 3 years in the Quantitative Biosciences Department, and previously worked as a post-doctoral scientist at Eli Lilly and Cornell University where he worked on understanding the role of innate immune receptors in autoimmune disease. William obtained his Ph.D. from UTMB where his worked focused on innate immune response to herpes virus infection.

Laura Struzyna, Ph.D.

Laura Struzyna earned her BSE in biomedical engineering from Duke University, after which she worked as a research technician for two years in a Neurosurgery lab at the University of Pennsylvania. She went on to earn her PhD in Bioengineering in the Cullen lab at the University of Pennsylvania in 2019. Her thesis work focused on developing a tissue engineering-based strategy to reconstruct the nigrostriatal pathway that degenerates in Parkinson's disease. In June 2019, Laura joined the Quantitative Biosciences Department within Merck Research Labs as a postdoctoral fellow under the mentorship of Marla Watt, PhD. Here, Laura is building upon her tissue engineering background to develop 3D cellular models for target validation and compound screening.